Company intelligence / Profile preview
Timmune Biotech
- Ownership
- Private
- Development stage
- Other
01
Overview
No recent reports of development identified in Phase I trials for leukemia or non-Hodgkin’s lymphoma in China as of May 2022. Early-stage clinical activity focused on allogeneic tri-functional CAR-NK cells showing potential immunologic cytotoxicity mechanisms but no published efficacy data yet available publicly
- Therapeutic areas
- Oncology
- Modalities
- Cell therapies including CAR-NK cell therapiesfusion protein molecule drugs
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
Exclusive China licensing agreement between Beike Biotechnology and Altor Bioscience for ALT-803
Beyond the preview
Go deeper on Timmune Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Timmune Biotech.